Cb1 receptor antagonist for the treatment of liver fibrosis

CB1 were highly induced in human cirrhotic samples and in liver fibrogenic cells. Treatment with specific CB1 antagonist decreased the wound-healing response to acute liver injury and inhibited progression of fibrosis in three mouse models of chronic liver injury. Similar changes are observed in CB1-deficient mice as compared to wild-type mice. CB1 promotes pro-fibrogenic effects. (Julien et al., Gastroenterology. 2005 Mar;128(3):742-55. ; Teixeira-Clerc et al., Nat Med. 2006 Jun;12(6):671-6. ; Mallat et al., Br J Pharmacol. 2011 Aug;163(7):1432-40.)

Keywords: Cannabinoid receptors, CB1, CB1 antagonist
Patent Application number: EP04290633.9
Inventors:
Sophie LOTERSZTAJNJeanne TRAN-VAN-NHIEUAriane MALLATBoris JULIENPascale GRENARD
Publications:
Julien et al. Gastroenterology. 2005 Mar;128(3):742-55. ; Teixeira-Clerc et al. Nat Med. 2006 Jun;12(6):671-6. ; Mallat et al. Br J Pharmacol. 2011 Aug;163(7):1432-40.

Reference:

BIO03318-T1

Business Developper
contact
Aymeric Empereur
Aymeric Empereur
Business Developer
Patent filling date: 2004-03-09

You might also be interested in